A Novel Method to Improve Validity and Relevance of Indirect Comparison and Network Meta-Analysis

Precision’s Jeroen Jansen and scientific advisor David Phillippo present an introduction to a novel analysis method, multilevel network meta-regression (ML-NMR). The method addresses several limitations with current methods, including synthesizing networks of any size and availability of IPD or aggregate studies, and – crucially for decision-making – producing estimates in any target population of interest. Moderated by Precision’s Ross Maclean.

––

Evidence Challenges and Synthesis Solutions for Health Economic Modeling

Learn how to utilize innovative approaches and models to improve the credibility of cost-effective models for disease treatment! Moderated by Precision’s Ross Maclean, Jeroen Jansen and Shannon Cope share their unique perspectives and solutions.

–

Does COVID-19 Threaten the Progress Pharmaceuticals Have Made in Reducing Cancer Mortality Over the Last 20 Years?

While the development and introduction of new pharmaceuticals have played a pivotal role in reducing US cancer deaths. However, Precision’s Joanna MacEwan and co-authors write that winning the war on cancer is a multifaceted battle. Meanwhile, COVID-19 has affected virtually every aspect of cancer care, from the research and development of new therapies, to diagnosis and treatment.

–

COVID-19: Models, Mathematics, and Myths

Researchers have introduced mathematical models of varying complexity over the past several months to capture different aspects of COVID-19’s dynamics, with limited to no implications for healthcare decision-makers. Why? Precision’s Anuj Mubayi and Ross Maclean identify the five myths surrounding COVID-19 mathematical models, and share potential answers regarding the extent to which each myth is addressed in the existing models.

–

Pharma’s Role in Maintaining Cancer Mortality Progress During COVID-19

Research suggests that new cancer treatments have played an especially important role in reducing mortality rates in certain cancers over the past several decades. Precision’s Joanna MacEwan and Ross Maclean discuss the disruption to the industry from the COVID-19 pandemic threatens this progress.

–